Therapies in the Pipeline for Systemic Autoimmune Diseases

*Juan Felipe Betancur,1 Jose Fernando Molina,2 Gabriel J. Tobón3

1. Department of Internal Medicine, Clínica Medellín, Medellin, Colombia
2. Rheumatology Department, Reumalab-centro integral de reumatología, CES University, School of Medicine, Medellín, Colombia
3. Department of Internal Medicine, Division of Rheumatology, Fundación Valle del Lili Cali, Colombia, ICESI University, School of Medicine, Cali, Colombia
*Correspondence to juanfebp@hotmail.com

Disclosure: The authors have declared no conflicts of interest.
Received: 10.03.16 Accepted: 10.05.16
Citation: EMJ Rheumatol. 2016;3[1]:118-127.

Abstract

The current goals in the development of novel therapeutics of systemic autoimmune diseases are to develop agents more effective than conventional therapies as well as to reduce the risk of organ damage. To achieve this goal, large multicentre randomised controlled trials are needed to confirm the efficacy and safety of novel agents. Whether these novel modalities are synergistic to conventional drugs, the optimal dosages, and duration of treatment, need to be explored.
As expected, the development of new molecules for the treatment of autoimmune diseases is constant, and there are different ongoing clinical trials. We review the different molecules in the pipeline, summarised in Tables 1, 2, and 3. We also show the successes, failures, and molecules that require more evidence.

Download (PDF, 143KB)

Comments are closed.